{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:34:47Z","timestamp":1790372087802,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NIH NCI","doi-asserted-by":"publisher","award":["RO1 CA237414-04"],"award-info":[{"award-number":["RO1 CA237414-04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA250959-01"],"award-info":[{"award-number":["P01 CA250959-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.esmoop.2024.104111","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T10:53:40Z","timestamp":1737197620000},"page":"104111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2"],"prefix":"10.1016","volume":"10","author":[{"given":"X.","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Grinshpun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kirkner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Scholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Meyerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.D.","family":"Cherniack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.W.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Jeselsohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2024.104111_bib1","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.21873\/anticanres.16625","article-title":"Prognostic value of HER2-low status in ER+ early breast cancer: a systematic review and meta-analysis","volume":"43","author":"Petrelli","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.esmoop.2024.104111_bib2","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1186\/s12885-023-11421-0","article-title":"Clinicopathological features and prognosis of patients with HER2-low breast cancer","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2024.104111_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102538","article-title":"Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: a systematic review and meta-analysis","volume":"115","author":"Ergun","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2024.104111_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.7239","article-title":"Examination of low ERBB2 protein expression in breast cancer tissue","volume":"8","author":"Fernandez","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2024.104111_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13058-023-01739-9","article-title":"High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients","volume":"25","author":"Nielsen","year":"2023","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.esmoop.2024.104111_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.esmoop.2024.104111_bib7","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2024.104111_bib8","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/s41374-022-00804-9","article-title":"Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer","volume":"102","author":"Moutafi","year":"2022","journal-title":"Lab Invest"},{"key":"10.1016\/j.esmoop.2024.104111_bib9","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2024.104111_bib10","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The Cancer Genome Atlas Pan-Cancer analysis project","volume":"45","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.esmoop.2024.104111_bib11","doi-asserted-by":"crossref","first-page":"993","DOI":"10.5858\/arpa.2023-0950-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer","volume":"147","author":"Wolff","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.esmoop.2024.104111_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101231","article-title":"7P Independent validation of HER2DX ERBB2 mRNA score to predict HER2-positive (HER2+), HER2-low and HER2-0 status in breast cancer","volume":"8","author":"Torres","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2024.104111_bib13","author":"Therneau"},{"key":"10.1016\/j.esmoop.2024.104111_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.esmoop.2024.104111_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.esmoop.2024.104111_bib16","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.esmoop.2024.104111_bib17","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.esmoop.2024.104111_bib19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"10.1016\/j.esmoop.2024.104111_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.esmoop.2024.104111_bib21","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","article-title":"A\u00a0pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells","volume":"184","author":"Cheng","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.esmoop.2024.104111_bib22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","article-title":"Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis","volume":"45","author":"Schietinger","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.esmoop.2024.104111_bib23","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1220688110","article-title":"Convergent and divergent effects of costimulatory molecules in conventional and regulatory CD4+ T cells","volume":"110","author":"Wakamatsu","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.esmoop.2024.104111_bib24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nature12988","article-title":"In\u00a0vivo discovery of immunotherapy targets in the tumour microenvironment","volume":"506","author":"Zhou","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2024.104111_bib25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2024.104111_bib26","article-title":"The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes","volume":"7","author":"Pereira","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2024.104111_bib27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41586-019-1007-8","article-title":"Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups","volume":"567","author":"Rueda","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2024.104111_bib28","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2024.104111_bib29","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.esmoop.2024.104111_bib30","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.1038\/s41467-023-43324-w","article-title":"Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer","volume":"14","author":"Tarantino","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2024.104111_bib31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13073-022-01104-z","article-title":"Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas","volume":"14","author":"Berrino","year":"2022","journal-title":"Genome Med"},{"key":"10.1016\/j.esmoop.2024.104111_bib32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF01961241","article-title":"Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2\/neu","volume":"24","author":"Benz","year":"1992","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2024.104111_bib33","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1158\/0008-5472.CAN-07-2707","article-title":"Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function","volume":"68","author":"Massarweh","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2024.104111_bib34","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1101\/gad.1944810","article-title":"Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance","volume":"24","author":"Lupien","year":"2010","journal-title":"Genes Dev"},{"key":"10.1016\/j.esmoop.2024.104111_bib35","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.3390\/cancers13112824","article-title":"HER2-low breast cancer: molecular characteristics and prognosis","volume":"13","author":"Agostinetto","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2024.104111_bib36","first-page":"1177","article-title":"Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer","volume":"8","author":"Tarantino","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2024.104111_bib37","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/bcr3145","article-title":"ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer","volume":"14","author":"Pinhel","year":"2012","journal-title":"Breast Cancer Res"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924018829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924018829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:43:53Z","timestamp":1762598633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924018829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2059702924018829"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.104111","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.104111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104111"}}